Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Abbott Laboratories : REPORTS THIRD-QUARTER 2020 RESULTS, ACHIEVES STRONG DOUBLE-DIGIT EARNINGS GROWTH AND RAISES GUIDANCE

10/22/2020 | 09:17am EST

ABBOTT PARK - Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2020.

Third-quarter worldwide sales of $8.9 billion increased 9.6 percent on a reported basis and 10.6 percent on an organic basis, which excludes the impact of foreign exchange.

Reported diluted EPS from continuing operations under GAAP was $0.69 and adjusted diluted EPS from continuing operations, which excludes specified items, was $0.98, reflecting 16.7 percent growth versus the prior year.1

Abbott projects full-year 2020 diluted EPS from continuing operations on a GAAP basis of at least $2.35 and full-year adjusted diluted EPS from continuing operations of at least $3.55.

In August, Abbott received FDA Emergency Use Authorization for its BinaxNOW COVID-19 Ag Card rapid test for the detection of COVID-19 infection. The test delivers results in just 15 minutes with no instrumentation required. Abbott is selling the test for $5 and offers a complementary mobile phone app, called NAVICA, that allows people who test negative to display their result.

During the quarter, Abbott launched FreeStyle Libre 2 and obtained CE Mark for FreeStyle Libre 3, which automatically delivers up-to-the-minute glucose readings, unsurpassed 14-day accuracy2 and real-time glucose alarms in the world's smallest and thinnest3 wearable sensor at the same affordable price4 as previous versions. Abbott also announced CE Mark for its Libre Sense Glucose Sport Biosensor, which helps athletes better understand the efficacy of their nutritional choices on training and athletic performance.

In September, Abbott obtained CE Mark for MitraClip G4, its next-generation MitraClip heart device, the leading minimally invasive mitral valve repair device in the world.

'Our strong results and increased guidance are a direct reflection of our ability to innovate and deliver despite challenging conditions,' said Robert B. Ford, president and chief executive officer, Abbott. 'Our new product pipeline continues to be highly productive, and we're well-positioned to finish the year with a lot of momentum.'

ABBOTT'S GUIDANCE FOR 2020

Abbott projects full-year 2020 diluted earnings per share from continuing operations under GAAP of at least $2.35. Abbott forecasts specified items for the full-year 2020 of $1.20 primarily related to intangible amortization, acquisition-related expenses, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be at least $3.55 for full-year 2020.

ABBOTT DECLARES 387TH CONSECUTIVE QUARTERLY DIVIDEND

On Sept. 17, 2020, the board of directors of Abbott declared the company's quarterly dividend of $0.36 per share. Abbott's cash dividend is payable Nov. 16, 2020, to shareholders of record at the close of business on Oct. 15, 2020.

Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

Contact:

Scott Leinenweber

Tel: 224-668-0791

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ABBOTT LABORATORIES
11/20ABBOTT LABORATORIES : Change in Directors or Principal Officers (form 8-K)
AQ
11/19ABBOTT LABORATORIES : Becomes first anchor sponsor of american diabetes associat..
AQ
11/18ABBOTT LABORATORIES : Launches the first infant formula in canada with an ingred..
AQ
11/17ABBOTT LABORATORIES : Launches the First Infant Formula in Canada with an Ingred..
AQ
11/17ABBOTT LABORATORIES : Named industry sustainability leader for the eighth year i..
AQ
11/16HHS Official Says The Agency Has Responded To Every State That Has Requested ..
RE
11/16ABBOTT : Named Industry Sustainability Leader for the Eighth Year in a Row on th..
PR
11/12ABBOTT LABORATORIES : Entry into a Material Definitive Agreement, Termination of..
AQ
11/12ABBVIE : Vice Chairman, Chief Commercial Officer Carlos Alban to Retire
DJ
11/11ABBOTT LABORATORIES : Announces the u.s. launch of the ionicrf generator for use..
AQ
More news
Financials (USD)
Sales 2020 33 873 M - -
Net income 2020 4 415 M - -
Net Debt 2020 11 794 M - -
P/E ratio 2020 44,6x
Yield 2020 1,32%
Capitalization 194 B 194 B -
EV / Sales 2020 6,07x
EV / Sales 2021 5,28x
Nbr of Employees 107 000
Free-Float 88,9%
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 118,44 $
Last Close Price 109,27 $
Spread / Highest target 19,0%
Spread / Average Target 8,40%
Spread / Lowest Target -25,0%
EPS Revisions
Managers
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Miles D. White Executive Chairman
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES25.80%193 666
MEDTRONIC PLC-2.19%149 189
BECTON, DICKINSON AND COMPANY-15.99%66 229
HOYA CORPORATION25.50%44 928
BAXTER INTERNATIONAL INC.-9.39%38 705
ALIGN TECHNOLOGY, INC.70.79%37 579